Heron Therapeutics, Inc. (HRTX)
After hours:
| Previous close | 2.7700 |
| Open | 2.7400 |
| Bid | 2.7100 x 200 |
| Ask | 2.7200 x 200 |
| Day's range | 2.6950 - 2.9599 |
| 52-week range | 0.5000 - 3.2200 |
| Volume | |
| Avg. volume | 2,612,735 |
| Market cap | 407.392M |
| Beta (5Y monthly) | 1.71 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- PR Newswire
Heron Therapeutics to Host Investor Day on May 15, 2024 in New York City
Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company, today announced that it will host an Investor Day on Wednesday, May 15, 2024 in New York City, beginning at 9:30 am ET. The event will include presentations from members of the Company's leadership team highlighting the renewed focus across the Acute Care and Oncology franchises and panel discussions featuring patient and physician experience with Heron's commercial products. The presentations will also include up
- PR Newswire
Heron Therapeutics Announces Presentation at the 23rd Annual Needham Virtual Healthcare Conference
Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company, today announced that Craig Collard, Chief Executive Officer of Heron, will participate in a fireside chat on Wednesday, April 10, 2024, at 11:00 AM ET at the 23rd Annual Needham Virtual Healthcare Conference. The conference is being held in a virtual format, April 8-11, 2024.
- PR Newswire
Heron Therapeutics Announces Fourth Quarter and Full-Year 2023 Financial Results and Highlights Recent Corporate Updates
Heron Therapeutics, Inc. (Nasdaq: HRTX) ("Heron" or the "Company"), a commercial-stage biotechnology company, today announced financial results for the three and twelve months ended December 31, 2023 and highlighted recent corporate updates.
